Literature DB >> 20498396

Economic implications of 21-gene recurrence score assay: US multicenter experience.

John Hornberger, Gary H Lyman, Rebecca Chien.   

Abstract

Mesh：

Year:  2010        PMID： 20498396     DOI： 10.1200/JCO.2010.28.8944

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.

Authors:  Shi-Yi Wang; Weixiong Dang; Ilana Richman; Sarah S Mougalian; Suzanne B Evans; Cary P Gross
Journal:  J Clin Oncol       Date:  2018-04-16       Impact factor: 44.544

2.  Cost-utility analysis of 21-gene assay for node-positive early breast cancer.

Authors:  L Masucci; S Torres; A Eisen; M Trudeau; I Tyono; H Saunders; K W Chan; W Isaranuwatchai
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

3.  Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care.

Authors:  Jennifer S Haas; Su-Ying Liang; Michael J Hassett; Stephen Shiboski; Elena B Elkin; Kathryn A Phillips
Journal:  Breast Cancer Res Treat       Date:  2011-06-17       Impact factor: 4.872
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.